Natixis Advisors’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $610K | Sell |
18,473
-26,992
| -59% | -$891K | ﹤0.01% | 1428 |
|
|
2025
Q1 | $1.83M | Buy |
45,465
+11,806
| +35% | +$474K | ﹤0.01% | 1108 |
|
|
2024
Q4 | $1.58M | Sell |
33,659
-3,936
| -10% | -$185K | ﹤0.01% | 1172 |
|
|
2024
Q3 | $1.99M | Sell |
37,595
-9,846
| -21% | -$520K | ﹤0.01% | 1089 |
|
|
2024
Q2 | $2.57M | Sell |
47,441
-3,035
| -6% | -$164K | 0.01% | 968 |
|
|
2024
Q1 | $3.54M | Sell |
50,476
-12,486
| -20% | -$875K | 0.01% | 886 |
|
|
2023
Q4 | $5.26M | Buy |
62,962
+19,124
| +44% | +$1.6M | 0.01% | 734 |
|
|
2023
Q3 | $1.29M | Sell |
43,838
-4,665
| -10% | -$137K | ﹤0.01% | 1109 |
|
|
2023
Q2 | $1.58M | Buy |
48,503
+8,652
| +22% | +$282K | ﹤0.01% | 1036 |
|
|
2023
Q1 | $1.4M | Buy |
39,851
+6,104
| +18% | +$215K | ﹤0.01% | 1048 |
|
|
2022
Q4 | $1.55M | Sell |
33,747
-2,458
| -7% | -$113K | 0.01% | 1020 |
|
|
2022
Q3 | $1.75M | Buy |
36,205
+1,216
| +3% | +$58.9K | 0.01% | 931 |
|
|
2022
Q2 | $1.38M | Buy |
34,989
+12,641
| +57% | +$497K | 0.01% | 1019 |
|
|
2022
Q1 | $823K | Sell |
22,348
-338
| -1% | -$12.4K | ﹤0.01% | 1174 |
|
|
2021
Q4 | $1.03M | Buy |
22,686
+2,970
| +15% | +$135K | ﹤0.01% | 1118 |
|
|
2021
Q3 | $705K | Buy |
19,716
+2,577
| +15% | +$92.1K | ﹤0.01% | 1153 |
|
|
2021
Q2 | $339K | Sell |
17,139
-772
| -4% | -$15.3K | ﹤0.01% | 1265 |
|
|
2021
Q1 | $416K | Sell |
17,911
-971
| -5% | -$22.6K | ﹤0.01% | 1191 |
|
|
2020
Q4 | $392K | Buy |
+18,882
| New | +$392K | ﹤0.01% | 1151 |
|